Gene | Genetic variant | Entrez Gene ID [31] | Major Allele | Minor Allele | Number of Cases | Number in Comparison Group | Country | Key Results | Included in meta-analysis |
---|---|---|---|---|---|---|---|---|---|
ANPEP | rs25651 | 290 | T | C | 560 severe | 950 non-severe infections | US & Canada | 0.69 odds of severe disease [59] | Noa |
G | A | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
CACNA1H | rs113802594 | 8912 | A | G | 1330 severe | 919 non-severe infections | US & Canada | 8.58 odds of encephalitis [61] | No |
CCR5 | CCR5 Δ32 | 1234 | – | Δ32 deletion | 560 severe | 950 non-Severe infections | US & Canada | No significant association with disease [59] | Yes |
– | Δ32 deletion | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
– | Δ32 deletion | 422 symptomatic | 331 asymptomatic infections | US & Canada | No significant association with disease [62] | ||||
– | Δ32 deletion | 634 infections | 422 controls | US | No significant association with disease, but significant association with more severe disease (p = 0.0016) [46] | ||||
– | Δ32 deletion | 395 symptomatic (two cohorts of 247 and 148) | 1318 controls | US | Significantly associated with disease in two cohorts (OR = 4.4 [1.6–11.8] and OR = 9.1 [3.4–24.8]), and fatal outcomes in one cohort with OR = 13.2 [1.9–89.9] [63] | ||||
HERC5 | rs148556308 | 51,191 | A | G | 1330 severe | 919 non-severe infections | US & Canada | Significantly associated with severe disease (p-value = 6.5 × 10− 10) [61] | No |
IRF3 | rs2304207 | 3661 | G | C | 422 severe | 331 asymptomatic infections | US | 0.52 odds of symptomatic infection under dominant model [62] | Noa |
G | C | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
MIF | rs5844572 | 4282 | 5 or 6 CATT repeats | 7 CATT repeats | 518 severe | 514 non-severe | US & Canada | 1.73 odds of encephalitis among patients with high-expression allele as compared to all other types of WNV disease [64] | No |
MX1 | rs7280422 | 4599 | C | G | 39 severe | 61 controls | Israel | 4.05 odds of infection associated with variant allele [60] | Noa |
C | G | 422 severe | 331 asymptomatic infections | US | 0.25 odds of symptomatic infection under a recessive model [62] | ||||
OASL | rs3213545 | 8638 | C | T | 422 severe | 331 asymptomatic infections | US | No significant association with disease [62] | Yes |
C | T | 39 severe | 61 controls | Israel | 1.85 (1.03–3.3) odds of infection [60] | ||||
C | T | 33 symptomatic | 60 controls | US | Significantly associated with disease (P < 0.004) [65] | ||||
OAS1 | rs10774671 | 4938 | A | G | 422 severe | 331 asymptomatic infections | US | No significant association with disease [62] | Yes |
A | G | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
A | G | 501 seropositive | 552 controls | US | 1.6 [95% CI 1.2–2.0] odds of seroconversion [66] | ||||
OAS1 | rs34137742 | 4938 | C | T | 422 severe | 331 asymptomatic infections | US | 9.79 [95% CI 3.60–26.61] odds of encephalitis and paralysis [62] | Yes |
C | T | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
RFC1 | rs2066786 | 5981 | T | C | 560 severe | 950 non-severe infections | US & Canada | 0.68 odds of severe disease associated with minor allele [59] | Noa |
G | A | 39 severe | 61 controls | Israel | 2.8 odds under dominant model [60] | ||||
SCN1A | rs2298771 | 6323 | C | T | 560 severe | 950 non-severe infections | US & Canada | 1.47 odds of severe disease associated with minor allele [59] | Noa |
A | G | 39 severe | 61 controls | Israel | No significant association with disease [60] | ||||
TFCP2L1 | rs11122852 | 29,842 | A | T | 1330 severe | 919 non-severe infections | US & Canada | 3.57 odds of severe disease and 4.94 odds of Acute Flaccid Paralysis than controls [61] | No |